6-Hydroxydopamine hydrobromide (Synonyms: 6-hydroxy Dopamine, Oxidopamine, 2,4,5-Trihydroxyphenethylamine) |
| رقم الكتالوجGC16267 |
أوكسيدوبامين (6-OHDA) هي مضاد للمحول العصبي دوبامين.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 636-00-0
Sample solution is provided at 25 µL, 10mM.
6-Hydroxydopamine hydrobromide (6-OHDA) is a structural analogue of catecholamines, dopamine and noradrenaline, and exerts its toxic effects on catecholaminergic neurons. The neurotoxin 6-hydroxydopamine continues to constitute a valuable topical tool used chiefly in modeling Parkinson's disease (PD) in the rat [1].
The classical method of intracerebral infusion of 6-Hydroxydopamine hydrobromide, involving a massive destruction of nigrostriatal dopaminergic neurons, is largely used to investigate motor and biochemical dysfunctions in Parkinson's disease [1]
6-Hydroxydopamine hydrobromide undergoes robust auto-oxidation generating cytotoxic H2O2, reactive oxygen species (ROS) and catecholamine quinones which attack endocellular nucleophilic groups [2].
Neurotoxic effects of 6-Hydroxydopamine hydrobromide occur through a two-step mechanism involving accumulation of the toxin into catecholaminergic neurons, followed by alteration of cellular homeostasis and neuronal damage. Intracellular storage of 6-Hydroxydopamine hydrobromide is mediated by the dopamine or noradrenaline membrane transporters (DAT and NAT respectively), which recognize and uptake 6-Hydroxydopamine hydrobromide due to its structural similarity with endogenous catecholamines [3]. 6-Hydroxydopamine hydrobromide is infused unilaterally in the MFB, producing a functional imbalance between the dopaminergic nigrostriatal systems and resulting in motor slowness, indicative of parkinsonian-like akinesia, and typical rotational behaviour in response to dopaminomimetic agents [4].
References:
[1]. Simola N, Morelli M, Carta A R. The 6-hydroxydopamine model of Parkinson's disease[J]. Neurotoxicity research, 2007, 11(3): 151-167.
[2]. Palumbo A, A Napolitano, P Barone and M d'Ischia (1999) Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration. Chem. Res. Toxicol. 12, 1213-1222.
[3]. Luthman J, A Fredriksson, E Sundstrom, G Jonsson and T.Archer (1989) Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav. Brain.Res. 33, 267-277.
[4]. Ungerstedt U and G Arbuthnott (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493.
| Cell experiment [1]: | |
Cell lines | Primary nigral cells (PNCs) |
Preparation Method | The conditioned media were replaced with new media containing AS-IV at the final concentration indicated with or without 200 µM of 6-Hydroxydopamine hydrobromide. |
Reaction Conditions | 200µM for 24 hours |
Applications | Compared with vehicle controls, exposure to 200 µM 6-Hydroxydopamine resulted in the loss of 75% of PNCs, as determined using the LDH assay. |
| Animal experiment [2]: | |
Animal models | Female Sprague-Dawley rats |
Preparation Method | The animals received a single, intrastriatal injection of 6-Hydroxydopamine hydrobromide. Twenty-five micrograms of 6-Hydroxydopamine hydrobromide, which was dissolved in 1.5 µl of normal saline with 0.2% ascorbic acid, was injected at a depth of 5.6 mm ventral to the skull at the same anterior/posterior and medial/lateral coordinates at which the cells had been injected. The injection site was chosen to be midway between the two implant sites. 6-Hydroxydopamine hydrobromide was injected over 5 min, and the needle was left in place for an additional 5 min before withdrawal of the needle. |
Dosage form | 25 µg in 1.5 µl of normal saline with 0.2% ascorbic acid |
Applications | Induced neurodegeneration in the SNc by unilateral injection of 6-hydroxydopamine hydrobromide into mfb, act as 6-OHDA lesion model |
References: | |
| Cas No. | 636-00-0 | SDF | |
| المرادفات | 6-hydroxy Dopamine, Oxidopamine, 2,4,5-Trihydroxyphenethylamine | ||
| Chemical Name | 5-(2-aminoethyl)benzene-1,2,4-triol hydrobromide | ||
| Canonical SMILES | OC(C(CCN)=C1)=CC(O)=C1O.Br | ||
| Formula | C8H11NO3.HBr | M.Wt | 250.09 |
| الذوبان | ≥ 25mg/mL in DMSO with ultrasonic | Storage | Store at 4°C,stored under nitrogen,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9986 mL | 19.9928 mL | 39.9856 mL |
| 5 mM | 0.7997 mL | 3.9986 mL | 7.9971 mL |
| 10 mM | 0.3999 mL | 1.9993 mL | 3.9986 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *